Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell Limited is making significant progress in the US market with its nerve repair product, Remplir™, as part of its strategic commercialisation plan. The company has conducted ten surgeries using Remplir in the US, demonstrating growing familiarity among surgeons. Orthocell has submitted 36 applications to hospital Value Assessment Committees, with three approvals received, marking a crucial step towards broader adoption. Additionally, Orthocell has shipped 4,000 Remplir units to its US logistics provider and expanded its US team to support the rollout, indicating a strong commitment to capturing market share and driving revenue growth.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, as well as products like Remplir™ for peripheral nerve reconstruction and SmrtGraft™ for tendon repair. The company is actively expanding its market presence in the US and other regions.
Average Trading Volume: 685,197
Technical Sentiment Signal: Buy
Current Market Cap: A$299.9M
Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.